Denali Therapeutics Inc. 4DN.F Stock
Denali Therapeutics Inc. Price Chart
Denali Therapeutics Inc. 4DN.F Financial and Trading Overview
Denali Therapeutics Inc. stock price | 20.49 EUR |
Previous Close | 29.82 EUR |
Open | 29.51 EUR |
Bid | 29.51 EUR x 0 |
Ask | 29.87 EUR x 0 |
Day's Range | 29.51 - 29.51 EUR |
52 Week Range | 20.01 - 37.47 EUR |
Volume | 65 EUR |
Avg. Volume | 60 EUR |
Market Cap | 4.04B EUR |
Beta (5Y Monthly) | 1.319014 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.87 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 85.5 EUR |
4DN.F Valuation Measures
Enterprise Value | 2.85B EUR |
Trailing P/E | N/A |
Forward P/E | -13 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 39.813473 |
Price/Book (mrq) | 4.1739745 |
Enterprise Value/Revenue | 28.096 |
Enterprise Value/EBITDA | -7.567 |
Trading Information
Denali Therapeutics Inc. Stock Price History
Beta (5Y Monthly) | 1.319014 |
52-Week Change | 39.00% |
S&P500 52-Week Change | 20.43% |
52 Week High | 37.47 EUR |
52 Week Low | 20.01 EUR |
50-Day Moving Average | 24.76 EUR |
200-Day Moving Average | 27.04 EUR |
4DN.F Share Statistics
Avg. Volume (3 month) | 60 EUR |
Avg. Daily Volume (10-Days) | 20 EUR |
Shares Outstanding | 136.89M |
Float | 123.21M |
Short Ratio | N/A |
% Held by Insiders | 14.58% |
% Held by Institutions | 79.22% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -389.36% |
Gross Margin | -295.66% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -18.086% |
Return on Equity (ttm) | -39.32% |
Income Statement
Revenue (ttm) | 101.46M EUR |
Revenue Per Share (ttm) | 0.79 EUR |
Quarterly Revenue Growth (yoy) | -16.60% |
Gross Profit (ttm) | -250269000 EUR |
EBITDA | -376710016 EUR |
Net Income Avi to Common (ttm) | -370552000 EUR |
Diluted EPS (ttm) | -2.71 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 1.29B EUR |
Total Cash Per Share (mrq) | 9.41 EUR |
Total Debt (mrq) | 57.09M EUR |
Total Debt/Equity (mrq) | 5.91 EUR |
Current Ratio (mrq) | 3.388 |
Book Value Per Share (mrq) | 7.07 |
Cash Flow Statement
Operating Cash Flow (ttm) | -231408992 EUR |
Levered Free Cash Flow (ttm) | -100189128 EUR |
Profile of Denali Therapeutics Inc.
Country | Germany |
State | CA |
City | South San Francisco |
Address | 161 Oyster Point Boulevard |
ZIP | 94080 |
Phone | 650 866 8548 |
Website | https://www.denalitherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 430 |
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative and lysosomal diseases in the United States and internationally. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease; TAK-594/DNL593, which is in Phase I/II clinical trials for the treatment of frontotemporal dementia-granulin; TAK-920/DNL919, which is in Phase I clinical trials for the treatment of Alzheimer's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); SAR443820/DNL788, which is in phase II clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreements with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, Genzyme Corporation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Q&A For Denali Therapeutics Inc. Stock
What is a current 4DN.F stock price?
Denali Therapeutics Inc. 4DN.F stock price today per share is 20.49 EUR.
How to purchase Denali Therapeutics Inc. stock?
You can buy 4DN.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Denali Therapeutics Inc.?
The stock symbol or ticker of Denali Therapeutics Inc. is 4DN.F.
Which industry does the Denali Therapeutics Inc. company belong to?
The Denali Therapeutics Inc. industry is Biotechnology.
How many shares does Denali Therapeutics Inc. have in circulation?
The max supply of Denali Therapeutics Inc. shares is 142.61M.
What is Denali Therapeutics Inc. Price to Earnings Ratio (PE Ratio)?
Denali Therapeutics Inc. PE Ratio is now.
What was Denali Therapeutics Inc. earnings per share over the trailing 12 months (TTM)?
Denali Therapeutics Inc. EPS is -0.87 EUR over the trailing 12 months.
Which sector does the Denali Therapeutics Inc. company belong to?
The Denali Therapeutics Inc. sector is Healthcare.